Last reviewed · How we verify

NCT06636201

Large-scale Multi-omics Analysis of Cerebrospinal Fluid

Recruiting now Last updated 10 October 2024
What this trial tests

trial in Aging in 150 participants. Currently enrolling.

Timeline
1 March 2024
Primary endpoint
1 March 2025
1 April 2025

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150
Start date1 March 2024
Primary completion1 March 2025
Estimated completion1 April 2025
Sites1 location across China

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 0 to 90, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to explore the role of cerebrospinal fluid (CSF) biomarkers in aging and neurodegenerative diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06636201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing